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ABSTRACT
Treatment with essential metalloelement (Cu, Fe, Mn, and Zn) chelates or combinations of them before
and/or after radiation injury is a useful approach to overcoming radiation injury. No other agents are known to
increase survival when they are used to treat after irradiation, in a radiorecovery treatment paradigm. These
chelates may be useful in facilitating de novo syntheses of essential metalloelement-dependent enzymes
required to repair radiation injury. Reports of radioprotection, which involves treatment before irradiation,
with calcium-.channel blockers, acyl Melatonin homologs, and substituted anilines, which may serve as
chelating agents after biochemical modification in vivo, as well as Curcumin, which is a chelating agent, have
been included in this review. These inclusions are intended to suggest additional approaches to combination
treatments that may be useful in facilitating radiation recovery. These approaches to radioprotection and
radiorecovery offer promise in facilitating recovery from radiation-induced injury experienced by patients
undergoing radiotherapy for neoplastic disease and by individuals who experience environmental,
occupational, or accidental exposure to ultraviolet, x-ray, or ,-ray radiation. Since there are no existing
treatments of radiation-injury intended to facilitate tissue repair, studies of essential metalloelement chelates
and combinations of them, as well as combinations of them with existing organic radioprotectants, seem
worthwhile.
INTRODUCTION
Essentiality and Speciation of Cu, Fe, Mn, and Zn In Vivo
Copper, iron, manganese, and zinc are essential metalloelements like sodium, potassium, calcium,
magnesium, chromium, cobalt, and vanadium. These essential metalloelements as well as essential amino
acids, essential fatty acids, and essential cofactors (vitamins) are required by all cells for normal metabolic
processes but cannot be synthesized de novo and dietary intake and absorption are required to obtain them.
Amounts of Cu, Fe, Mn, and Zn found in body tissues and fluids [1,2] correlate with the number and kind of
metabolic processes requiring them. However, there may be decreases in tissue content due to inadequate
dietary intake and absorption associated with soil depletion, socioeconomic circumstances, and aging-related
declines in consumption.
Ionic forms of these metalloelements have particularly high affinities for organic ligands Ibund in
biological systems and rapidly undergo bonding interactions to form complexes or chelates in biological
systems. Calculated amounts of ionic Cu (10-8M), Fe (10-23M), Mn (10-2M), and Zn (lO-gM) in plasma [3]
are extremely small and not measurable with existing equipment. Concentrations of these ionically bonded
essential metalloelements are likely to be even smaller in solid tissues, which contain many,’ more bonding
ligands. Consequently, measured tissue Cu, Fe, Mn, and Zn contents reflect tissue contents of chelates. These
are primarily metalloelement-dependent enzymes (Table 1), proteins such as Hemoglobin, Femtin,
Metallothioneines 0VITs), 132-Macroglobulins, and Tmnsfen’in, as well as RNA and DNA chelates, small
molecular mass amino acid, carboxylic acid, phosphate, amine, diamine, and thiol chelates and various small
molecular mass peptide chelates [4 and cited refs.]. Ionically bonded metalloelement compounds will
immediately form coordinate-covalent bonded chelates in biological systems as a result of bonding interactions
with components of these systems capable of these bonding interactions. To study effects of essential
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metalloelements m a biological system it is most inappropriate to use ionically bonded forms of a particular
metalloelement and most appropriate to use relevant chelates, which have particularly important roles in
mediating biochemical repair of radiation injury via ligand exchange processes.
Table I. Established and recently suggested Cu, Fe, Mn, and Zn dependent mammalian enzymes.
Cu-dependent enzymes [4-19]
Cytochrome c Oxidase
Extracellular and Cytosolic
Cu-Dependent and Zn-Modulated
Superoxide Dismutases (Cu2Zn2SOD)
Tyrosinase
Dopamine-13-Mono-Oxygenase
Neurocuprein
Amine Oxidases
Factors V and VIII
Ceruloplasmin
a-Amidatmg Mono-Oxygenases
Procollagen and Proelastin
Peptidyllyl Oxidases
Pfion Protein
Methionine Synthase
Amyloid Precursor Protein
Plasma Pituitary. Adenylate Cyclase-Activating
Polypeptide
CCS
Other possible Cu-dependent enzymes [20-24]
Adenylate Cyclase
Guanylate Cyclase
Lipolytic Protein
ACE and CUP2
Iron-dependent enzymes [5,25]
Electron Transport Cytochromes
including Cytochmme c Oxidase
Catalase
P-450s
Lipoxygenase
Cyclo-Oxygenase
Xanthine Oxidase
Peptidylprolyl and
Peptidyllysyl Oxidases
Catechol Dioxygenases
Nitric Oxide (Nitrogen Monoxide) Synthase
Function
Reduction of oxygen
Superoxide disproportionation
Synthesis of dihydroxyphenylalanine
Synthesis of norepinephrine and epinephrine
Synthesis of norepinephrine and epinephrine
Metabolism ofprimary amines
Blood clotting
Cu transport, mobilization of stored Fe, and
angiogenesis, down-regulation of nitric
oxide synthase (NOS)
Synthesis of neuroendocrine hormones
including: gastrin, choleocystokinin,
melanoeyte stimulating hormone, ealeitonin,
vasopressin, secretin, and some enkephalins
Collagen and elastin cross-linking
Normal metalloglycoprotein located on the
extracellular surface of many cell types of
unknown function
Synthesis of methione from homocysteine
May have a role in decreasing amyloid A
protein synthesis and increasing secretion of
amyloid precursor protein
Activates Adenylyl Cyclase and
Modulates inducible Nitric Oxide
Synthase (NOS)
Cu Chaperone for Cu2ZngSOD
Synthesis ofc-AMP
Synthesis ofc-GMP
Lipolysis
Metallothioneine
regulatory proteins
gene transcription
Oxidation-Reduction
Disproportionation of hydrogen peroxide
Activation of oxygen
Conversion of arachadonic acid to 5-HPETE
and 5-HETE
Conversion of aracadonic acid to PGG2
Purine metabolism
Hydroxylation of procollagen and proelastin
Oxidative opening of catechol ring systems
Synthesis of nitrogen monoxide
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Manganese-dependent enzymes [5,26-32]
Mn-Dependent SOD
Argmase
Pyruvate Carboxylase
Pseudocatalase
Calmodulin-Dependent Protein
Phosphatase
ot-Isopropylmalate Synthetase
A Brain Adenylate Cyclase
Catechol-O-Methyltransferase
Farnesyl Pyrophosphate Synthetase
Glycosyl Synthetase
Extradiol-Cleaving Dioxygenase
A Ganglioside Galactosyl-
Saccharide Polymerases
Glycosyltransferases tmnsferase
A Galactosylhydroxylysyl
connective Glucosyltransferase
Phosphatases
Restriction Endonucleases
Xylose Isomerase
Catalases
Extradiol-Cleaving Catechol Dioxygenases
Zinc-dependent enzymes [5,33-36]
Cu2Zn2SOD
Ammopeptidase
Aldehyde Hydrase
Esterase
Methylmalonyl-Oxaloacetate
Transcarboxylase
CarboxypeptidasesA and B
NAD-Dependent Dehydrogenases
Carbonic Anhydrase
c-Hydroxyacid Dehydrgenase
Alkaline Phosphatase
Ptu-ine and Pyrimidine
Nucleoside Kinases
DNA Polymerase and Gyrase
"Zinc-Finger" proteins
Matrix Metalloproteinases
Metal-Responsive Transcription Factor-
Disproportionation of superoxide
Syntheses of urea and omithine
Synthesis of oxaloacetate
Disproportionation ofH202
Phosphate ester hydrolysis
Synthesis of c-isopropylmalate
Synthesis ofc-AMP
Synthesis of catechol methyl ether
Synthesis offamesyl pyrophosphate
Synthesis of glyeosyl-phosphonueleotides
Insertion of dioxygen
Galactose transfer
Synthesis of polymeric carbohydrates
Synthesis of glycosides
Glycosaminoglycan and
tissue component syntheses
Phosphate ester hydrolysis
DNA recognition and cleavage
Isomerization of xylose
Disproportionation of hydrogen peroxide
Oxidative opening of eatechol ring systems
glycoprotein
Dispmportionation of supemxide
Protein hydrolysis
Aldehyde hydration
Ester hydrolysis
Transcarboxylation
Protein hydrolysis
Oxidations
Dehydration of carbonic acid
Oxidation of {x-hydroxy acids
Phosphorylation
Phosphorylation ofnucleosides
DNA synthesis
Transcription regulating proteins
Endopeptidases required for repair,
maintenance, and function of extracellular
connective tissue components and wound
repair
Metalloelement transcription factor, a
Zn-finger regulatory protein required for
cellular response in metalloelement uptake
Essential Metalloelement Metabolism
Ingested foods and beverages contain these essential metalloelements in chelated forms, which may
yield other chelates as a result of ligand exchange in the digest or following absorption [4]. However, some of
the absorbed chelates may exist in the digest and in blood as the original chelate or a more stable ternary
chelate. Absorbed metalloelement chelates undergo systemic circulation to all tissues and utilization by all
cells following ligand exchange with small molecular mass ligands, apoproteins, and apoenzymes to form
metalloproteins and metalloenzymes in de novo syntheses. These metalloelements are stored in the appropriate
tissues as MTs or Fe-Ferritin, or they are excreted in the event tissue needs have been met and stores
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replenished [4]. There are no inducible excessive storage diseases known in normal individuals. Hovever,
there must be upper limits dictated by physiological requirements.
Stored essential metalloelements are released as chelates via ligand exchange to meet normal
metabolic needs. This homeostatic release of relatively small amounts of essential metalloelement chelates
meets normal physiologic requirements. Release of larger quantifies in a pronounced mobilization of these
metalloelements is a feature of interleukin-1 (IL-1) and other cytokine mediated acute and chronic responses to
many disease states [4 and cited refs].
It is likely that the magnitude of these responses is adequate in normal well-nourished individuals and
allows them to overcome their disease. However, it is now generally recognized that dietary intakes of Cu, Fe,
Zn [37,38], and most likely Mn are less than recommended daily intakes for the U.S. population and may be no
better for individuals living in other developed countries. Individuals who have depleted stores of these
essential metalloelements, such as chronic disease patients, may overcome pathology associated with their
disease state, which always involves inflammation, more slowly or not at all. The degree of radiation injury
and the nutritional state of health of an individual may determine whether or not an individual will be able to
overcome metalloelement-dependent repairable radiation injury. Treatment with essential metalloelement
chelates either before and/or after radiation injury may support these essential metalloelement-dependent
responses or facilitate recovery regardless of the state of nutriture.
Chemical Consequences of Ionizing Radiation
Since water represents 70% of the chemical composition of the adult body (90% of the infant body),
its chemical transformation by ionizing radiation merits serious consideration with regard to chemical
consequences of ionizing radiation. Ionizing radiolysis of water is well understood and produces very. reactive
aquated electrons, monoatomic hydrogen atoms, hydroxyl radical, hydrogen peroxide, and protonated water as
well as superoxide (O2-) and hydroperoxyl radical in the presence of oxygen. Hydroperoxyl radical, hydroxyl
radical, monoatomic hydrogen, and aquated electrons have very short half-lives of the order of milliseconds
and consequently react rapidly with cellular components in reduction, oxidation, initiation, insertion,
propagation, and addition reactions causing loss of function and the need for biochemical replacement and/or
repair. Ionizing radiation can also impart sufficient energy to all biochemicals to cause homolyltic bond
breaking and produce all conceivable organic radicals in considering C-C, C-N, C-O, C-H, P-O, S-O, etcetera
bond homolyses. These radicals will undergo the above listed radical reactions to cause further destruction and
the need for replacement and/or repair. A third consequence of ionizing radiation is homolytic or heterolytic
bond breaking of coordinate-covalent bonded metalloelements. These are the weakest bonds in biochemical
molecules and potential sites of greatest damage, which may be most in need of replacement and/or repair
since many repair enzymes are metalloelement-dependent.
Recognizing that loss of essential metalloelement-dependent enzyme activity may at least partially
account for lethality of ionizing radiation and that Cu-, Fe-, Mn-, and Zn-dependent enzy.mes have roles in
protecting against accumulation of O- as well as facilitating repair [39] may explain the radiation protection
and radiation recovery" activities of Cu, Fe, Mn, and Zn compounds. It is suggeed that the IL-1 mediated
redistributions of essential metalloelements have a general role in responding to radiation injury.. These
redistributions may also account for subsequent de novo synthesis of metalloelement-dependent enz3’mes
required for biochemical repair and replacement of cellular and extracellular cofiaponents needed for recover
from radiolytic damage.
De novo syntheses of metalloelement-dependent enzymes required for utilization of o.xTgen and
prevention of O2- accumulation as well as tissue repair processes including metalloelement-dependent DNA
and RNA repair are key to the hypothesis that essential metalloelement chelates decrease and/or facilitate
recovery from radiation-induced pathology. A widely held understanding is that O_- accumulates in
mammalian cellular and extracellular spaces due to the lack of normal concentrations of Cu and Zn-or Mn-
dependent superoxide dismutases (SODs), inappropriate reduction of O_ leading to relatively large steady-state
concentrations of O2-, or inappropriate release of O.- from oxygen activating centers. Increasing synthesis of
O- as the result of the conversion of Xanthme Dehydrogenase, which does not synthesize O,.-, to Xanthine
Oxidase which does synthesize 02- has been recently demonstrated in the liver of 3 to 9 Gray (Gy) irradiated
mice [40]. More reactive oxygen-radicals derived from 02- include: singlet oxygen and hydrogen peroxide,
produced as a result of acid-dependent self disproportionation or water-catalyzed dispt)portionation of O_-.
hydrox3’l radical, and hydroperoxyl radical [41,42]. Facilitated de now syntheses of Cu_Zn_,SODs and catalase
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and decreasing or preventing formation of these oxygen-radicals may account for some of the recovery from
pathological changes associated with irradiation, which cause systemic inflammatory disease and immuno-
incompetency in the case of whole-body irradiation, and focal inflammatory., disease associated with local
irradiation.
Radiation-Induced Tissue Injury
Ionizing radiation is known to cause a variety of tissue injuries at all levels of biochemical systems.
Acutely toxic radiation syndromes are well known in terms of doses of radiation and clinical courses of these
syndromes [43]. Doses of radiation that are less than those that cause death in the short term as well as
ultraviolet irradiation cause a variety of disease states depending upon the biochemical injury of the affected
tissues. Consequences of ionizing and ultraviolet irradiation are a matter of current concern. Radiation risk of
fatal malignancy associated with commonly performed coronary angiography was found to be around in
6,000 with a risk of fatal lung cancer of about in 8,000, an increase of 0.017% above the normal incidence for
the general population [44]. Longer and more complicated procedures carry a greater risk consistent with the
well known phenomenon of radiation-induced carcinogenesis [45]. Radiation-Induced skin injury, is also an
unwanted consequence of this procedure and more so for all ex vivo irradiations of neoplastic tumors [44].
Adult CF male rats x-irradiated with 0.015 centiGy see
1 day
1 for 7 days followed by 7 days rest for
either 3 months or 6 months showed duration related patchy skin hyalinization, which became completely
hyalinized during the succeeding 6 months without irradiation [46]. The concentration of Zn in skin of these
rats remained normal in both irradiated groups but by the end of yr it had significantly (P < 0.001) decreased
to 13 lag grn" of tissue from 19 lag grn". Skin Fe was elevated in both irradiated groups and the elevation
increased from 100 lag gm" of tissue with 3 mo irradiation to 140 lag grn after 6 mo irradiation versus 68
gm
"1 for control skin, There was a hmher relative increase in skin Fe yr after irradiation to 129 tg grn
"1 of
tissue compared to 65 lag gm for control skin (P< 0.001). It was concluded that chronic exposure to low dose
x-irradiation possibly causes a redistribution of Zn and Fe with concomitant hyalinization of collagen. The
observed skin collagen pathology and altered essential metalloelement contents were interpreted as results of
chronic inflammation due to chronic irradiation [46].
Recent studies of pregnant women who resided in a heavily exposed area of the Republic of Belarus
following the Chemobyl catastrophe appear to be at risk for development of toxemia, renal insufficiency, and
anemia. Neonates born in heavily contaminated areas were found to be at risk for development of anemia,
congemtal malformations, and perinatal death. Decreased concentrations of erythrocyte Cu and Zn were
documented for these neonates. Diminished white blood cell, T-helper cell, and T4 cell counts were found for
neonates from areas ofheavy exposure [47].
Radiation Protection and Recovery with Copper Chelates.
Small non-toxic doses of Cu(II)2(3,5-DIPS)4 ranging form 5 to 80 amol kg-
of body mass increased
survival of lethally irradiated mice treated orally or subcutaneously (sc) before irradiation, while smaller doses
ranging down to 2.5 rnol Cu(II)2(3,5-DIPS)4 kg given sc 3 hr after irradiation, the radiation recover?.."
paradigm, also increased survival [48 and cited refs.]. In a recent radiorecovery study, doses of 5, 10, or 20,
lamol Cu(II)2(3,5-DIPS)4 kg
"1 given 3 hr after LDs0/0 (8 Gy, 1.4 Gy min"1) irradiation produced sua’vivals of
52%, 606, or 52%, increases of 63%, 88% (P < 0.05), or 63%, respectively, compared to vehicle-treated
control mice, and also facilitated recovery of radiation-reduced loss of body mass (P < 0.05) and recovery of
radiation-induced loss of physical activity (locomotion) (P < 0.001) [49].
Doses of 5, 10, or 20 lamol Cu(II)CI2, or 5, 10, or 20 pmol Cu(II)2(3,5-DIPS)4 kg
-1 administered sc 3
hr after LD50/30 whole-body irradiation facilitated recovery of radiation-induced stemic inflammatow
disease, recovery of lost body mass, and increased survival. Treatment with 5, 10, or 20 lamol Cu(II)CI_, kg:
produced 7%, 21,% or 29% increases in survival, respectively, compared to the vehicle-treated group, which is
consistent with the activity reported by others [see 48]. However, treatment with 5, 10, or 20 lamol Cu(II)2(3,5-
DIPS) kg" produced increases of 44%, 67%, or 44% survival, respectively, compared to the vehicle-treated
group. The recovery of radiation-induced loss in body mass and increased survival of mice treated with either
Cu(II)CI2 or Cu(II)2(3,5-DIPS)a document that both Cu compounds are effective mdiorecove)" agents.
However Cu(II)2(3,5-DIPS), the more bioavailable form of Cu is more effective than Cu(II)CI_ [50].
All radiation protection and radiation recovery doses of Cu(II)2(3,5-DIPS)4 Cu(II)_(3,5-DIPS)4 are
non-toxic and ranged from 1/5 to 1/100 of an acutely toxic dose (LDs0/7) for male or female mice [see 48]. The
LD50/7, acute toxicity, of Cu(II)2(3,5-DIPS) in female mice and rats, 261+36 tmol kg, was much higher than
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observed for male mice and rats, 91+13 prnol kg". Acutely lethal doses of Cu(II)2(3,5-DIPS)4 produce marked
CNS depression due to loss of parasympathetic regulation of cardiac and pulmonary function. Smaller doses
produce short duration hypnotic or sedative eftLcts. The small doses of Cu(II)2(3,5-DIPS4 exhibiting
radioprotectant and radiorecovery activity do not produce any of these CNS depressant effects. Of perhaps still
greater interest with regard to many studies of supposed "Cu-mediated toxicity" as having a role in an
"oxidative etiology", suggested to account for pathology of many disease states, is the recent report pointing
out that these studies were seriously flawed [51]. The same increase in 532 nm absorbance measured
following the addition of thiobarbituric acid to disease-related biological systems to which ionically bonded
forms of Cu had been added to "catalyze oxidations", was observed following addition of ionieally bonded Cu
to aqueous solutions of only thiobarbituric acid. The linear increase in this 532 nm absorbance was related to
the increase in Cu-thiobarbiturate chelate(s)formation.
Initial studies involving treatment of LD00/50 irradiated mice ffter irradiation employed a dose of 80
prnol Cu(II)2(3,5-DIPS)4 kg
"1 which was found to be effective in increasing survival when given before
irradiation. However this dose given nfter irradiation caused acute lethality, all of these treated mice died
before the vehicle-treated mice (non-published). The rationale for this observation is that treatment with this
large dose of Cu(II)2(3,5-DIPS)4 niter irradiation interfered with de novo synthesis of other essential
metalloelement-dependent enzymes required for repair of radiation injury and decreased survival. That is, only
a fraction of the dose given before radiation remains when radiation-injury occurs and this fraction is useful in
overcoming radiation-injury and increasing survival. Giving this large dose of Cu(II)2(3,5-DIPS)4 ffter
irradiation may interfere with the synthesis of other metalloelement-dependent enzymes by enabling
incorporation of the incorrect metalloelement, in this case Cu, when the larger dose is given ffter radiation
injury. This possibility also offers a rationale for historical observations that large doses of Cu, Fe, Mn, and Zn
compounds cause "radiosensitization", reducing survival and increasing radiation-induced mortality. Large
doses of aminothiol radioprotectants that are effective in increasing survival of lethally irradiated mice when
given before irradiation are also lethal when given ter irradiation.
Mechanistic Modes of Cu Chelate Action.
The copper chelate of 5-diethylsulfonarnoylsalicylic acid [Cu(II)(5-DESS)] has been recently reported
to be effective m increasing survival of LDs0/30 (8 Gy, 1.4 to 1.3 Gy min) irradiated mice. Treatment with O,
20, 40, 60, 80, 100, or 120 prnol kg
l given sc before irradiation revealed that 80 or 120 prnol kg-
produced
significant increases in survival, 68% (P 0.019) or 92% (P 0.0008), respectively, compared to vehicle-
treated control mice [52].
Copper(II)(3,5-DIPS)4 did not prevent hematopoietic and immunologic damage to irradiated mice,
since 98-99% of myeloid progenitor cells were destroyed and immune reactivity was ablated. However,
Cu(II),_(3,5-DIPS) did accelerate cellular repopulation of bone manw and spleen following irradiation.
Recovery of hematopoietic activity was accelerated whether mice were treated with Cu(II)2(3,5-DIPS) 3 hr
before or 3 hr after irradiation and treatment increased levels of multipotential progenitor cells, which serve as
a sotu’ce of both myeloid and lymphoid progenitor cells, to account for recovered responses to T and B cell
mitogens and antibody responses to a T-dependent antigen [see 48].
Radiorecovery and/or radioprotectant activity of Cu-containing compounds or complexes should be
recognized as possibly facilitating activation of Cu-dependent proteins and enzymes required for repair of
radiation injury, including induction of metallothioneine (MT) synthesis, and recovery of radiation-induced
immuno-incompetency. In this context, cytokines such as interleukm-1 OL-1), tumor necrosis factor, stem cell
factor, and interleukin-12 have recently been suggested to restore function to tissues damaged by irradiation
and protect mice from radiation lethality when given before irradiation [53]. In contrast, cytokines such as
transforming growth factor I, interleukin-6, and interferon, given before irradiation, sensitize mice and
increase radiation lethali.ty [54]. It is most likely that there are complex cytokine interactions relevant to the
amount of cytokine nthesized and timing of release in responding to the degree of radiation injury.
Additional evidence for this comes from the correlation between survival of irradiated keratinocytes and the
synthesis of IL-6 [55]. It is also known that changes in ceruloplasmin (Cp), a Cu-dependent multifunctional
plasma enzyme, the plasma Zn containing a2-macroglobulin, and transferrin, the plasma Fe transporter,
mediated responses to injury are regulated by IL-1 and other cytokines m facilitating tissue repair processes.
Addition of inflammatory cytokines; IL-lt, IL-II or inorganic Cu to hepatocyte culture medium increased
mRNA Ibr MT-I, MT-2, and Cp in a coordinated cytokine-activation of hepatic cells as an acute phase
response to inflammation [56]. These observations offer a clearer understanding of the well-known cytokine-
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mediated acute phase response to inflammation and the increase in Cp as an acute phase response to
irradiation-induced inflammation.
Following the observed radioprotectant and radiorecovery activities of Cu(II)(3,5-DIPS)4 as well as
its facilitation of recovery of radiation-induced immuno-ineompetency, the question still remained as to
whether or not there was any correlation between these observations and repair or recovery of radiation-
induced histopathology. To address this need histopathologieal studies of spleen, bone marrow, thymus, and
small intestine were conducted in parallel with immunological studies of animals exposed to LD50/0 irradiation
(8.0 Gy, 1.55 Gy min"a) alone, treatment with 40 anol kg
"1 Cu(II)2(3,5-DIPS)4 alone, or irradiated and treated
with a single dose of vehicle or Cu(II)2(3,5-DIPS). Treatment with Cu(II)2(3,5-DIPS) brought about repair of
radiation-induced histopathology in these tissues [see 48]. Signs of recovery were demonstrable by the 7th to
14th day after irradiation. These observations lead to the general conclusion that although Cu(II)(3,5-DIPS)
does not prevent tissue injury when it is given before irradiation. Treatment with this chelate facilitates rapid
tissue recovery from radiation-induced injuries. These recoveries from radiation-induced histopathology offer
a biological marker for the re-establishment of the integrity of tissues known to be most vulnerable to
irradiation.
The earlier review [see 48] also pointed out that Cu(II)2(3,5-DIPS)4 inhibits radiation-induced
carcinogenesis and clastogenesis consistent with suppression of DNA replication and blockade of cell growth
in the S phase as well as repair of DNA strand breaks. These effects are also consistent with reported
anticlastogenic activity of Cu(II)(glycinate)2, observed as a rapid recovery of bone marrow cell radiation injury
and associated repair of DNA [see 48]. They are also consistent with the prevention or repair of DNA strand
breaks by Cu(II).(indomethaeinate)4 in phorbol-treated human leukoeytes and support Cu-dependent
mechanisms for prevention or repair of radiation-inducedDNA damage.
Whole body and local irradiation injury constitutes either systemic or local inflammation. Consistent
with the antiinflammatory activities of Cu chelates [57], Cu(II)=(3,5-DIPS) has been found to be effective in
facilitating repair of systemic inflammation caused by whole body irradiation (vide supra) and local
inflammatory reactions. Ear swelling of female C3H mice treated 2 hr before porphyrin photosensitization
and visible (480 to 645 nm) irradiation with 20, 40, or 80 btmol kg
"1 Cu(II)2(3,5-DIPS)4 produced dose-related
decreases in porphyrin-mediated photosensitized ear swelling of 25%, 50%, or 90%,reslxmtively, with a
dramatic decrease in photosensitization-induced histopathology, suggested to be O-mediated inflammation
due to activation of Xanthine Ox_idase (XO) [58]. This inflammation was inhibited by Allopurinol, an inhibitor
of XO, and Verapamil, a Ca-channel blocker (vide infra) suggested to prevent the isoenzyme transformation of
Xanthine Dehydrogenase (XD) to XO [59], the form of this enzyme that synthesizes H202 and 02. Consistent
with this suggestion, ultraviolet epidermal cell injury of mouse ears (ultraviolet erythema, a recognized model
of inflammation) was decreased with Cu:Zn2SOD treatment and inhibition of Cu2Zn2SOD by treatment with
diethyldithiocarbamate exacerbated the "sunburn call" formation but did not change dtraviolet radiation-
induced ear swelling [60]. Ultraviolet irradiated human endothelial cells elaborate nitrogen monoxide (NO)
which may account for vasodilation and ear swelling as an inflammatory response [61] following activation of
inducible Nitrogen Monoxide Synthase (NOS).
The observed decrease in skin Cu2Zn2SOD following a single ultraviolet irradiation was also reduced
by pretreatment with liposomes containing Cu2Zn2SOD [62]. Increased ultraviolet radiation-induced
keratinocyte proliferation was also found to be associated with a decrease in total SOD activity which was due
mainly to a decrease in Cu2Zn2SOD [63]. Protection against ultraviolet radiation-induced chronic skin damage
was also found with topically applied non-steroidal antiinflammatory agents [64]. These agents have been
suggested to tbrm Cu chelates in vivo [57], which may account for their inhibition or repair of ultraviolet
radiation induced injury.
Copper(II)2(3,5-DIPS)4 was originally examined for radioproteetant activity based upon reports that
Cu2Zn2SOD had radioprotectant activity when given both before and after irradiation. However, subsequent
reports suggested that superoxide dispmportionation by Cu2Zn2SOD did not account for its radioprotectant
activity. Inactivated polyethylene-glycol derivatized Cu2Zng_SOD was as effective as the enzymatieally active
derivative. The very real possibility that these proteins in extracellular spaces are in fact antigenic, although
reduced antigenicity is always claimed, may lead to phagocyte elaborated IL-I and/or some other cytokine(s)
that initiates immune and repair responses that accounted for the observed increase in survival [see 48].
The hypothesis that there are radiolytic losses of essential metalloelement-dependent enzyme
cofactors [see 48] has merit and is consistent with the report that them was a 20% loss of both Cu2Zn2SOD and
MnSOD in intestinal smooth muscle of rats immediately (1 hr) following irradiation (15 Gy). However, the
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activity of both enzymes increased over a 20 hr post-irradiation period to a level 45% higher than normal with
a further increase in Mn SOD by 72 hrs post irradiation, a likely result of de novo synthesis in response to
injury. It is noteworthy that Cu(II)(3,5-DIPS)4, a SOD-mimetic, was subsequently found to be more effective
as a radioprotectant and radiomcovery agent than CuzZnzSOD and more effective than WR-2721 in reducing
oxygen radical mediated colitis [65].
Adult CF male rots x-irradiated with 15 cGy see
"1 day
"1 for 7 days followed by 7 days rest for either 3
months or 6 months showed duration related radiation-induced patchy skin hyalinization, which became
completely hyalinized during the succeeding 6 months without irradiation [66]. The concentration of Zn in
skin of these rats remained normal in both irradiated groups but by the end of yr it had significantly (P <
0.001) decreased to 13 xg grn
"a of tissue from 19 lag gm. Skin Fe was elevated in both irradiated groups and
the elevation increased from 100 lag grn-of tissue with 3-mo irradiation to 140 lag grn
l after 6-mo irradiation
versus 68 lag grn
"a for control skin. There was a further relative increase in skin Fe yr after irradiation to 129
lag grn" of tissue compared to 65 lag grn
"1 for control skin (P < 0.001). It was concluded that chronic exposure
to low dose irradiation possibly causes a redistribution of Zn and Fe with concomitant hyalinization of
collagen. The observed skin collagen pathology and altered essential metalloelement contents were interpreted
as results of chronic inflammation due to chronic irradiation [66]. These changes in skin essential
metalloelement contents are consistent with essential metalloelement-dependent enzyme responses required to
overcome radiation injury.
Reduction in radiation-induced fibrosis with liposomal CuZn_SOD was studied using large white
pigs ,/-irradiated with a single dose of 160 Gy delivered to the skin. Treatment with 0.3 mol Cu2ZnzSOD
applied 2 times per week for 3 wk caused shrinking of irradiation-induced fibrosis in all treated pigs. Scar
regression was found to be 45% in length and width, 30,4 in depth, and 70% in area and volume. Histologic
examination showed normal muscle and subcutaneous tissue surrounding the residual scar. This replacement of
scar tissue by normal tissues and a 50O/ decrease in the linear dimensions of the scar were comparable to
results obtained in a previous clinical trial of liposomal CuZn_SOD treatment [67].
Over expression of Cuv_ZnSOD or MnSOD increased survival of 0.2 to 1.2 Gy (0.3 Gy min-) x-
irradiated CHO cells and cells over-expressing MnSOD had greater survivals that those over-expressing
Cu2Zn,,SOD [68]. As pointed out earlier [see 48] the SOD-mimetic reactivity of Cu(II)2(indomethacinate)4
was credited with the prevention of DNA strand-breaks in human leukocytes stimulated with phorbol-diester.
This prevention or facilitated repair of DNA was observed over a concentration range of 2 to 9 btM
Cu(II)2(indomethacinate)4.
Another possible mechanism offered to account for the radiopmtectant and radiorecovery activities of
Cu chelates involves Cu-dependent nuclear metabolism. It is known that 20% of cellular Cu is found in the
nucleus. Copper has the highest bonding affinity for nucleic acids of all essential metalloelements. Nucleic
acid phosphate and base donor sites yield Cu chelates, which are much more stable than Cu chelates of most
amino acids and near the stability of protein chelates. This stability has been used to support suggestions of
intrastrand and interstrand DNA bridging, which was recognized early as having a role in stabilization of the
Watson-Crick double helix [see 48]. Higher physiologic concentrations account for inhibition of ribonuclease
syntheses: initiation, nucleotide condensations, and release of newly formed mRNA. However, the original
observation that injection of Cu(II)CI2 into rats induced the synthesis ofmRNA coding for the synthesis ofMT
has been explained as due to the formation of a Cu-dependent DNA bonding protein ACE1 or CUP2, the
protein products of S. cerevisiae (ACE1) and E. coil (CUP2) genes, which recognize upstream activation
sequences required for active transcription of CUP1, a MT gene as pointed out earlier [see 48] ,and
subsequently [69]. Chaperones such as hAtoxl are Cu bonding proteins suggested to have roles in mediating
Cu homeostasis in many cell types as cytosolic Cu-transporters, enabling the utilization of Cu in tie novo
synthesis of Cu-dependent enzymes and proteins [70]. Since radiation injury and injection of Cu chelates
induce MT synthesis and increased MT synthesis correlates with increased survival, Cu chaperones such as
Atoxl, which mediate the role of Cu in transcription of Cu2Zn2SOD and the anti-apoptotic bcl-2 genes [71],
may represent important nuclear chemical responses in overcoming radiation injuB..’.
Nuclease-Mimetic reactivi.ty of Cu chelates has been recognized as valuable footprinting reagents
useful in revealing details of RNA polymerase bonding to a lac promoter [see 48]. Predictable chromatin
DNA cleavage by a chelate due to preferential bonding of the chelate to DNA spacer segments is also a useful
characterizing feature. Interpretations that these and other DNA strand scissions resulting from Cu chelates ae
damaging [72,73] without recognizing that these scissions may be due to expected Cu chelate [74] or other
essential metalloelement chelate [75] catalyzed diphosphate ester hydrolyses, which may be viewed as
222Metal BasedDrugs Vol. 8, No. 4, 2001
endonuclease- (or exonuclease-) mimetic reactivity, merit reconsideration. More recently, the antineoplastic
action of the copper complex of Tambjamine was suggested to be due to DNA nuclease reactivity [76].
Like many Cu chelates, Cu(II)(3,5-DIPS)4 has SOD-mimetic reactivity. While formation of ternary
protein-Cu(II)z(3,5-DIPS)4 chelates formed with collagen or albumin have slightly less SOD-mimetic reactivity
due to protein bonding to a free Cu bonding site [77], it is the formation of, as yet not unequivocally
demonstrated, ternary albumin chelates formed in vivo [78,79] that were suggested to account for the observed
rapid and pervasive tissue distribution of 67Cu and 1C labeled 3,5-DIPS within 0.5 hr following administration
of67Cu(IIh[3,5-DIP(Carboxy-1C)S] [80].
Dietary supplementation with arginine, the substrate for NOS, required for the synthesis of NO has
been found to accelerate intestinal mucosal regeneration and enhance bacterial clearance following radiation-
induced rat enteritis [81]. Rats fed diet containing 4% arginine for 7 days following non-lethal local abdominal
x-irradiation (11 Gy, 0.14 Gy min") had significantly (P<O.001) increased mesenteric lymph node mass,
decreased number of lymph node Gram-negative enteric bacilli and facultative anaerobic bacteria, CFU gm" of
lymph node, increased mucosal thickness, and jejunal and ileal villi height and number, as well as number of
mucous cell villi compared to rots fed a diet containing 2% arginine or 4% glycine.
Copper(II)(3,5-DIPS) has been suggested to facilitate NO mediated responses to inflammato
diseases [82,83]. However, it has also been found to decrease synthesis ofNO by down-regulating nitric oxide
synthase (NOS) enzyme activity which may account for the antiinflammatory activities of this and other Cu
chelates as well as repair of radiation injury [82,83]. This is an eially interesting possibility since Cp,
which increases in plasma following irradiation, has recently been reported to decrease NOS activity when
incubated with endothelial cells. There was a time-dependent increase in cytosolic and particulate bonded
copper, and this effect could be reproduced by incubation with Cu(II)(histidinate),,_ but not with Cu(II)CI2.
which primarily bonded to all particulate fractions and less so to cytosolic components [84]. In addition,
CuZn2SOD has recently been shown to release NO from S-nitrosothiols in the presence of glutathione [85]
suggesting that Cu2Zn.SOD might have a role in mediating constitutive or inducible NOS and facilitating NO-
mediated physiological functions as well as mediating rat mucosal regeneration and bacterial clearance in
radiation enteritis [81 ].
Recently a domain of Cp, distinct from the ferro-oxidase domain, has been reported to act as a
glutathione-dependent pemxidase [86] and a glutathione-dependent alk3’l hydroperoxidase [87], which offers
an interesting accounting for a plasma Cu-dependent agent responsible for removal of lipid hydroperoxides.
Cemloplasmin has also been recently identified as a plasma Pituitary Adenylate Cyclase-Activating
Polypeptide (PAC-AP) 1-38-bonding factor [88]. This factor is an alpha amidated peptide, one of many amide
terminus neuronal hormone peptides synthesized by Cu-dependent x-arnidating mixed function oxidases [89].
PAC-AP has more recently been reported to prevent cytokme-induced pancreatic B-cell cytotoxicit3" by
inhibiting inducible NOS expression in BTC cells [90]. The PACAP activity of Cp has also been reported to
decrease cytokine-induced cytotoxicity by inhibiting inducible NOS in pancreatic I cells [91]. These
observations offer an accounting for the radioprotectant and radiorecovery activities of Cu(II),,(3,5-DIPS)4.
since Cu(II)2(3,5-DIPS)4 has been reported to down-regulate, but not inhibit enzyme activib’, NOS and
decrease the synthesis of NO [81,82]. Alternatively, this Cu chelate as well as others may form ternar3
nitrogen monoxide chelates (ON-CuL2) that have a role facilitat.ng NO dependent processes [81,82].
The possibility remains that reported therapeutic actions of Cu chelates may be due to only a small
portion of the admimstered dose bonded to serum albumin and transported to the site of action. That is, an
effective antiinflammatory dose of Cu(II)2(3,5-DIPS)a is tmol per kilogram of body mass. This represents
1019 molecules per 70 kg adult treated with a supposed dose of 70 txrnol. If only 0.01% of this dose was
distributed throughout the body due to losses including excretion, each of the estimated 101" cells in the adult
body could experience contact with more than 1,000 molecules of this chelate. Since there is always ,an
inflammatory-response mediated vasodilation at the site of disease-affected cells and greater perfusion of these
affected cells by plasma filtrate, the concentration of drug in the environment of disease-affected cells could
actually be greater than 1,0 molecules per cell. Smaller daily doses ranging down to 0.7 tamol per adult,
which could be a more likely dose, would provide 10 molecules per cell with the loss of 99.99% of the
administered dose. Such losses may be typical for all administered drugs.
Radiation Protection trod Recovery with Iron Chelates.
Since radiolytie loss of Fe from Fe-dependent enzymes is also a possible consequence of ionizing
radiation, non-toxic doses of Fe(III)-(3,5-DIPS)3 were examined for radioprotectant activity. Doses ranging
from 35 to 280 gmol kg
1 given sc before irradiation produced increases of 50% to 84% survival of
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irradiated (8 Gy, 1.55 Gy mm1) male mice compared to vehicle-treated mice [see 48]. Treatment sc with 35
tmol Fe(III)-(3,5-DIPS)3 kg
"l before LDl00/30 irradiation increased survival 300% compared to vehicle-treated
mice (8% survival). Treatment with sc doses of 17.5, 35, or 70 larnol Fe(III)-(3,5-DIPS)3 kg
"1 fter LDl00t0
irradiation failed to increase survival above the 8% observed for vehicle-treated control mice [91].
Radiorecovery of mice treated with this chelate and irradiated with smaller doses of irradiation remain to be
determined.
Gamma irradiated (7 Gy, 2.9 Gy min1) young adult male DBA/2 mice treated with 16 mol kglip
Fe(III) hematoporphyrin chloride (FeHp) either and 4 days or 1, 4, and 7 days niter irradiation had
significantly (P < 0.025) increased spleen colony forming units (CFU-GM) by day 14 following irradiation
[92]. Mice treated on days and 4 after irradiation had significantly (P < 0.025) increased numbers of spleen
cells by day 17 post-irradiation. IronHp treatment on days 1, 4, and 7 also caused a significant (P < 0.005)
reduction in bone marrow cell number by day 14 and other post-irradiation periods of measurement. There
was no increase in bone marrow CFU-GM observed for any treatment. Mice treated 24 hr before irradiation
and 48 hr or 48 and 96 hr niter irradiation produced significant (P < 0.001) increases in total spleen cell
number and spleen CFU-GM by day 15 post-irradiation. The single treatment t’ter irradiation caused a 5-fold
larger increase in spleen CFU-GM number than non-irradiated or irradiated control values measured on day 15.
The only significant (P < 0.01) change in bone marrow cellularity was a decrease in cell number for mice
treated 4 hrs before and 48 and 96 hrs d’ter irradiation. There were no significant changes in bone marrow
CFU-GM number at any time of measurement on 11, 14, and 17 days post-irradiation, relative to irradiated
control mice. These data were interpreted as due to hematostimulatory activity of FeHp with stimulation
occumng following radiation-induced immunosuppression. Enhanced hematopoietic recovery was observed
for spleen but not bone marrow of irradiated mice treated with FeHp. Treatment may have also increased the
mobilization of progenitor cells from bone marrow to the spleen in addition to the FeHp stimulatory effects on
spleen CFU-GM. Interestingly, the FeHp-mediated spleen hematopoietic response was greatest in mice treated
24 hrs before irradiation. There was no "protection" but resting hematopoietic stem cells may have been
reduced to begin the cell growth cycle and division, while actively dividing cells would have been at gater
risk to radiation injury and cell death.
Radiation Protection and Recovery with Manganese Chelates.
The earlier review [see 48] cited a number of reports that inorganic Mn(II)CI2 given sc in the
radioprotectant paradigm before irradiation increased survival and enhanced survival when co-administered
with aminothiol radioprotectants. Following these reports Mn(II)C12 was shown to repair radiation-induced
skin and intestinal inflammation in mice [93]. Treatment with 180 lamol Mn(II)CI2 kg given ip to male C3H
mice 24 hr before a single 20 to 52 Gy (5 Gy min"1) local paw x-irradiation or 12 to 21 Gy abdominal
irradiation fed to repair of acute intestinal and skin radiation-injury. Skin and intestinal MT was not increased
by administration of MnCI2 although a six-fold increase was found in liver. These authors failed to point out
that the increase in liver MT was associated with the increase in survival of mice treated with Mn(II)C12.
Based upon the radioprotectant and radiorecovery activities observed for non-toxic doses of Mn-(3,5-
DIPS)2, which may either be a spherically symmetric trinuclear chelate, Mn(IIIhMn(II)t30(3,5-DIPS)6, or a
linear trinuclear chelate, Mn(II)3(3,5-DIPS)6, was examined for radioprotectant and subsequently for
radiorecovery activity [see 48]. Subcutaneous treatment with 90, 120, or 150 tmol Mn-(3,5-DIPS)2 kg
l 3 hr
after a LD70/0 irradiation again demonstrated that all three doses were effective, producing 200%, 229% or
214% increases in survival above vehicle-treated mice (28% survival) [93].
Treatment with 150 tamol Mn-(3,5-DIPS),, kg" before LD0o/30 irradiation and then 30, 60, or 120
tmol kg
-1 on three successive days after irradiation produced survivals of 28%, 12%, or 16% respectively
versus 0% survival for vehicle-treated mice [94]. Treatment with 90, 120, or 150 lamol kg
l 3 hrs after LDT0/30
irradiation increased survival from 7% for the vehicle-treated mice to 21%, 23%, or 22%, respectively, 200%
(P 0.00007), 229% (P 0.000005), or 214% (P 0.00002) increases in survival compared to vehicle-treated
mice [94]. Treatment with 150 tmol kg 3 hr before LD10o/30 irradiation (10 Gy, 1.4 Gy minl) and 90, 180, or
360 tmol kg
"1 on day 2, 4, and 6 after irradiation produced 28% (P 0.007), 12%, or 16% survival,
respectively, versus 0% survival for vehicle-treated mice. Treatment with 120, 240, or 480 lamol Mn-(3,5-
DIPS).. kg before LDlf/0 irradiation revealed that only the 240 and 480 lamol kg doses were effective,
producing survivals of 16% or 27%, respectively, with no surviving control mice [94]. Treatment with doses
of 60, 120, or 240 tmol Mn-(3,5-DIPS) kg after LD0oro irradiation revealed that only the 120 tamol kg
dose was efftive, increasing survival 233% above control mice (12% survival) [94].
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Oral treatment with Mn-(3,5-DIPS)2 before or after LD0o/30 irradiation increased survival and
recovery of radiation-induced loss of body mass [94]. Treatment with 120, 240, or 480 xrnol Mn-(3,5-DIPS)2
kg
"a orally 3 hr before irradiation or 60, 120, or 240 pmol kg" 3 hr after irradiation increased survival and
allowed greater recovery of radiation-induced loss of body mass compared to vehicle-treated mice. Treatment
with 120, 240, or 480 pmol Mn-(3,5-DIPS)2 kg
"l orally 3 hr before irradiation produced 4%, 16%, or 27%
stawival versus 0% for vehicle-treated mice. Treatment with 20, 120, or 240 mol Mn-(3,5-DIPS)2 kg" 3 hr
after irradiation produced 12%, 40%, or 4% survival versus 12% survival for vehicle-treated mice.
Mechanistic Modes ofMn Chelate Action.
A possible Mn-(3,5-DIPS)2 mechanism of action in overcoming inflammation due to radiation injury
is the dovn-regulation of NOS when excess NO is produced as part of the inflammatory response [82].
Alternatively, activation of Mn-dependent guanylyl cyclase [95], the receptor for NO, by Mn-(3,5-DIPS)z may
serve to restore normal physiologic functions involving NO-mediated processes. This understanding is
consistent with the suggestion that a ternary NO-Mn-(3,5-DIPS)z complex might form in vivo [82] and have
roles in mediatingNO function [83].
The Mn-Desfemoxamine (MnDFO) SOD-mimetic chelate has also been found to be effective in
protecting against riboflavin-mediated ultraviolet (365 nm, 2 to 9 J cm"2) phototoxicity [96]. Photohemolysis
of erythrocytes was decreased with 500 vl MnDFO. Treatment with 50 or 100 ONI MnDFO did not change
3H-Thymidine incorporation in irradiated (5 J cm"z) GH-U1 human urinary bladder carcinoma cells or
irradiated (10 J cm"2) phytohemaglutin-stimulated lymphocytes compared to radiation alone. Higher
concentrations ofMnDFO were toxic to these cells.
Hahn et al. [97] and Dart et al. [98,99] suggested that MnDFO is superior to Cu chelates as an SOD-
mimetic because Cu chelates dissociate in the presence of protein. This suggestion was offered even though
Cu chelates are much more effective in disproportionating O2" at an appropriate physiological pH and more
effectively treat many disease states (see 2). They overlook the fact that Mn chelates also dissociate in the
presence of protein or other biochemically important macromolecules via ligand exchange. However, these
losses may not prevent their use in treating diseases (vide supra et infra). More importantly they overlook the
possibility that the presence of protein such as albumin can lead to temary Cu or Mn chelate formation with
enhanced stability and serve as Cu or Mn chelate transporting agents in vivo [77-79]. Consequently, the view
that Cu or Mn chelates can not be effective SOD-mimetics in preventing Oz-mediated pathology, despite many
observations to the contrary is seriously flawed. Finally, Mn chelates will not serve to facilitate the activation
of Cu-dependent enzymes nor will Cu chelates facilitate activation ofMn-dependent enzymes.
The SOD-mimetic reactivity of Mn(III)tetrakis-l-methyl-4-pyridylporphyrin pentaehloride
[Mn(III)TMPyP] was recently suggested to aount for the restoration of NO-mediated neurotransmission and
serves as a lead compound in the development of SOD-mimetics as therapeutic agents for the treatment of
neuropathies associated with oxidant stress [100].
To examine the possibility that treatment with a combination of essential metalloelemem chelates
might be effective in increasing survival of lethally irradiated mice, Cu(II)z(3,5-DIPS)4 and Mn-(3,5-DIPS)z
were studied using a factorial design [101 ]. Treatment with 10, 20, or 40 vxnol Cu(II)2(3,5-DIPS)4 kg
"1 before
LDg0/30 irradiation (9 Gy, 1.25 Gy min"l) produced survivals of 28%, 28%, or 36% survival, respectively,
133%, 133%, or 200/5 increases above vehicle-treated mice (12% survival). Increasing the dose of
Cu(II)e,(3,5-DIPS) increased survival in these more rigorously radiation-injury-challenged mice. Treatment
with 10, 20, or 40 xnol Mn-(3,5-DIPS)z kg" before LDg irradiation (9 Gy, 1.25 Gy min"1) produced
survivals of 36%, 20/5, or 24% survival respectively, 200/5, 67%, or 100% increases in survival respectively,
compared to the same vehicle-treated mice. Increasing the dose of Mn-(3,5-DIPS)z did not produce a dose-
related increase in survival. Using combinations of 10, 20, or 40 pmol Cu(II)2(3,5-DIPS) and 10, 20, or 40
tmol Mn-(3,5-DIPS)2 kg
"l revealed that the combination of 20 tmol Cu(II)2(3,5-DIPS) plus 20 mol Mn-
(3,5-DIPS)_ kg
1 produced 48% survival, a 300% (P 0.01) increase above the same vehicle-treated mice.
While increasing the dose of Cu(II)2(3,5-DIPS)4 from 10 to 40 pmol kg" increased survival, increasing the
dose of Mn-(3,5-DIPS)2 fi’om l0 to 40 pmol kg
"l did not increase survival and increasing doses of Mn-(3,5-
DIPS)2 beyond 20 lamol kg
1 given in combination with Cu(II)z(3,5-DIPS)a were associated with decreases in
survival or no increase in survival due to combination-treatment. This apparent negative effect on survival
associated with increasing doses of Mn-(3,5-DIPS)_ given in combination with Cu(II)9(3,5-DIPS)4 may be due
to an interference of Mn in de novo synthesis of Cu or some other metalloelement-dependent enzymes wherein
the incorporation of Mn leads to a reduction in activity of non-Mn metalloelement-dependent enzymes
requiring a metalloelement other than Mn for activation.
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Irradiation-Induced esophagitis, micro-ulceration, and esophageal stricture as well as cytokine mRNA
elevations and squamous cell apoptosis were dramatically decreased in male C3H/HeNsd mice with intra-
esophageal instillation of mouse MnSOD-plasmid/liposome (SOD2-PL) 24 hr before 35 or 37 Gy local
esophageal x-irradiation (58). Mice bearing orthostatic thoracic tumors treated with mouse SOD2-PL also
evidenced esophageal transgenic SOD2 mRNA [102]. These results were suggested to provide support for
human SOD2-PL gene therapy in a fractional irradiation paradigm to avoid acute and chronic radiation-
induced side effects in a human clinical trial of pulmonary ttunor irradiation 102]. Increased stuwival was also
observed at both levels of irradiation. A significant increase in surviving fraction (1.0, P 0.0291) versus 0.5
for control liposome treated mice was observed for 35 Gy irradiated mice treated with 100 tg SOD2-PL/mouse
given by the mtra-esophageal route of administration with a significant (P 0.015) decrease in esophagitis in
this 30-day study. Mice irradiated with 37 Gy and treated with 200 xg SOD2-PL/mouse or 10 xg SOD2-
PL/mouse by intra-esophageal instillation experienced increased surviving fractions of 0.5 (P 0.05) or 0.7 (P
0.0119) respectively compared to non-treated irradiated mice in this 60-day study 102]. While mtra-trachael
instillation of transgene before irradiation protected C57BL/6J mice from whole-lung irradiation-induced
alveolitis/fibrosis, there was no significant lung protection in SOD2-PL treated SP1-SOD2 or FeVI3/NHsd
transgenic mice. Over expression of either human SOD2 or murme Sod2 in the lungs of these transgenic mice
did not provide local 11 to 15 Gy irradiated whole-lung or alveolar type II cell protection [103]. Over
expression of SOD2 in SP-1 SOD2 mice may have made these mice more sensitive to radiation injury.
However, these studies may have been seriously flawed since mice developing pulmonary distress were killed,
preventing the possible observation that treated mice might have overcome this radiation-induced
inflammatory complication.
Radiation Protection and Recovery with Zinc Chelates.
As pointed out in our earlier review [see 48] treatment with Zn compounds dramatically increased
survival of lethally irradiated mice. In the interim it was shown that fractional whole-body /-irradiation of
male BALB/C mice given a total doses of 0.5, 1, or 1.5 Gy induced an increase in DNA-protein cross-links in
the thymus, spleen, brain, and liver. However, when these mice were given drinking water containing 154
Zn(II)SO4 for 30 days DNA-protein cross-links were dramatically decreased to levels observed in all of these
tissues from non-irradiated mice 104].
Fibroblasts cultured in medium containing 100 p_M Zn(II)CI2 had repaired ultraviolet radiation-
induced DNA strand-breaks and delayed in apoptotic loss of nucleosomes [105] Cells cultured with 100 tM
Zn(II)C12 and irradiated with 1.4, 2.9, 3.6, or 5 J/cm2 actually evidenced more double-stranded DNA than non-
irradiated cells. This result suggests that Zn(II)CI2 prevents and/or repairs DNA strand-breaks Similarly,
apoptosis was always less in Zn(II)CI2 supplemented cells at all times of measurement; 0, 3, 6, 8, 11, 12, and
18 hrs after irradiation consistent with prevention and/or repair of irradiation-induced injury leading to
apoptosis. Gamma irradiation-induced thymocyte DNA strand-breaks and apoptosis were synergistically
decreased with combinations of Zn(II)SO4 and diethyldithiocarbamate, a compound known to form
Zn(II)(diethyldithiocarbamate)2 106].
Since addition of Zn (0.15 pM) to culture medium did not protect human’melanoma tells tlu’ough a
radiation dose range of 1.5 to 8.0 Gy (0.85 Gy minl). It had been suggested earlier [see 48] that the protective
effect of Zn was due to the facilitation of some homeostatic mechanism which was suggested to be induction
of MT synthesis [see 48]. Studies of MT gene regulation identified the involvement of bacterial
lipopolysaccharide, IL-I, interferon, and other immunostimulants with control of MT syntheis in the liver.
These observations coupled with the observation that IL-1 has radioprotectant activity [54] support the
hypothesis that MT synthesis has a role in reducing radiosensitivity. Induction of MT synthesis is a
physiological response to oxidant stress as described for IL-1 or endotoxin-mediated responses to this stress as
well as other cytokine-mediated responses to radiation injury. [58,59].
As pointed out earlier [see 48] Zn(II)(aspartate), is known to have radioprotectant activi:. An
important question as to whether or not this compound protected neoplastic cells from radiation inju.w was
answered when ip treatment with 90 pmol kg
"1 Zn(lI)(aspartate)2 did not inhibit 7-ray radiotherapcutic
reduction of tumor volume using three adenocarcinomas of the colon or Ewings sarcoma implanted
immunosuppressed mice [107]. Zinc(II)(aspartate). also significantly reduced radiation-induced decrease in
hematocrit and thrombocyte, erythrocyte, and leukocyte numbers, an indication of spleen and/or bone man’ow
precursor cell sparing effect or rapid recovery of immunocompetence. Zn(II)(aspartate)_ permitted a greater
226Metal BasedDrugs Vol. & No. 4, 2001
reduction in tumor volume than cysteamine [mercaptoethylamine (MEA)], mET, and WR-2721 and it was as
effective as a syngeneie bone marrow transplant [107].
Doses of 90 pmol Zn(II)(aspartate)2, 80 tmol Zn(II)(histidinate)2, 80 nol Zn(II)(orotate)2, or 122
pmol Zn(II)(acetate)2 kg given ip 3 hr before irradiation (3.5 to 7.25 Gy) facilitated post-irradiation recovery
of hematocrit, thrombocytes, erythrocytes, and leukocytes in C3H male and female mice [108]. Generally,
Zn(II)(aspartate)9., was more effective than the other Zn chelates and administration along with WR-2721
produced a marked synergistic increase in recovery of hematocrit and thrombocytes. Zinc(II)(aspartate)2 was
also the only Zn chelate that did not inhibit radiation-induced reduction in growth of adenocarcinoma-
implanted and immunosuppressed mice [108].
Small non-toxic doses of Zn(II)(aspartate)=, 45 pmol kg
-1 ip, and WR-2721 175 pmol kg
-1 ip, given
to female C3H mice 30 min or 10 min before LDl00/30 ,t-irradiation (10.5 Gy, 0.2 Gy min1) produced a
synergistic increase in survival of 83% versus 0% for vehicle-treated control mice 109]. Zinc(II)(aspartate),
45 mol kg ip, and WR-2721, 1,400 tmol kg ip, given to female C57BL/6 mice 30 min or 10 min before a
fractionated LD00/30 ,-irradiation (5 x 1.9 Gy) also produced a synergistic increase in survival of 83% versus
0% for vehicle-treated control mice. Fraetionated whole body radiation-induced carcinogenesis leading to
lymphoid tumors was dramatically decreased from 90,6 to 9% in C57BL/6 mice treated with
Zn(II)(aspartate)2, 45 pmol kglip, and WR-2721, 1,400 nol kg given ip. Thus this combination treatment
dramatically decreased radiation-induced lymphoid tumors [108].
The earlier review [see 48] pointed out that treatment with 60 tmaol Zn(II)2(3,5-DIPS)4 kg
1 produced
95% survival in LDs0r0 (8 Gy, 1.55 Gy min") irradiated male mice. Acute toxicity of this chelate was also due
to CNS depression with a sedative-hypnotic dose of 123 larnol kl". However, the effective dose of
Zn(II)(3,5-DIPS)4 was only 1/6 ofthe acute toxic dose 381+75 lamol kg-’.
Mechanistic Modes ofZn Chelate Action.
Since Zn chelates have no SOD-mimetic reactivity, activation or synthesis of Cu2Zn2SOD, MT, or
other Zn-dependent enzymes including endonucleases and other known and suspected Zn-dependent
transcription and translation processes [110] must at least partially account for their radioprotectant or
radiorecovery activity. Another partial accounting may be attributed to protection of spleen and bone marrow
stem cells by decreasing DNA replication and blockade in the S growth phase as observed tbr CHO cells
treated with Zn(II)CI. as pointed out earlier [see 48].
A 100 pmol kg" dose of Zn(II)-Desferrioxarnine [Zn-DFO] produced 60% survival in whole body
LD50/30 /-irradiated female C3H mice treated 0.5 hr before irradiation while Desferioxamine had no
radioproteetant activity [111]. There was no radioprotective effect observed in studies of cultured V79
Chinese hamster cells. However, Zn-DFO concentration dependently prevented radiation-induced plasmid
DNA strand-breaks through a concentration range of 0.5 to 2 mM.
Feeding an "antioxidant" diet containing 55 trnol Zn(II)(gluconate)2 kg-
day
l to C57BL male mice
for 45 days before irradiation(6 Gy, 1.8 Gy min") caused an inhibition of TRPM-2, a marker gene for
apoptosis expression both before and after irradiation [112]. The bcl-2 mRNA, which is involved in the
prevention of apoptosis, and splenocyte number increased steadily after irradiation. The expression of sod-I
gene increased and remained elevated for 24 hr, the last time of measurement after irradiation, and synthesis of
the eat (catalase) gene increased slightly shortly after irradiation and decreased by 3 hr after irradiation.
Preliminary studies under the same experimental conditions revealed a decrease in frequency of radiation-
induced mutations as evidenced by changes in the hypoxanthine-quanine phosphoribosyl-transferase locus of
splenocytes from mice fed the antioxidant diet containing Zn(II)(gluconate)2. The maximum antimutagenic
effect was detected by the 6th week of diet administration.
Radioprotectant and Radiorecovery Activity of Calcium-Channel Blockers.
New evidence provided by Floersheim and his colleagues document radioprotectant and radiorecovery
activities for some Ca-channel blockers [113-116]. These reports are consistent with the earlier suggestion of
Athar et al. [59] that Veraparnil, a Ca-channel blocker, prevents radiation injury-induced conversion of
Xanthine Dehydrogenase to Xanthine Oxidase, which synthesizes 02-.
Diltiazem, a benzothiadiazepine Ca-channel blocker, given sc as the hydrochloride salt in distilled
water to female mice at doses of 61, 122, or 244 rnol kg" 15 min before LD00/30 (10.5 Gy, 0.15 Gy min"1)
irradiation produced 17%, 58%, or 93% survival [113]. A dose of 244 nol kg
-1 given sc 10 rain after
irradiation produced 42% survival for this radiorecovery paradigm. Nifedipine, a dihydropyridine Ca-channel
blocker, given ip at a dose of 4 tmaol kg" in an ethanol vehicle, which provided 50 mmol ethanol kg, 30 min
227John R.J. Sorenson et al. EssentialMetalloelement Chelates Facifitate
Repair ofRadiation Injury
before LD00r0 irradiation (8.5 Gy, 0.9 Gy min") produced 100,4 survival and the vehicle produced 61%
survival, a difference of 39,4 [113]. Treatment with 5 Ixrnol Nimodipin kg", another dihydropyridine Ca-
channel blocker, produced 82% survival whereas the vehicle containing 43 mmol ethanol produced 42%
survival. Distilled water-treated mice experienced 0% survival. Male mice treated ip with 10 ’nol
Nimodipine kg
"1 30 min before LDl0030 8.1 Gy (0.9 Gy rain") irradiation produced 75% survival while
treatment with 9 lamol kg" ip Nifedipine (a dihydropyridine) produced 67% survival and the ethanol vehicle
produced 30% survival. Injection of distilled water produced 0% survival. However, ip treatment with a dose
of 10 tmol kg
1 Nimodipine or 9 lamol kg Nifedipine given before irradiation produced 58% survival while
the group treated with the ethanol vehicle had 0,4 survival [113].
Isradipine, another dihydropyridine Ca-channel blocker, given at a dose of 74 tmol kg" ip before
irradiation (9 Gy) produced 58% survival. Treatment with 278 ktmol kg
"1 Nitrendipine (a dihydropyridine Ca-
channel blocker), ip, produced 29% survival. Verapamil, a substituted aminopropylnitrile Ca-channel blocker,
given at a dose of 35 pmol kg
"1 ip and Flunarizine, a piperazine Ca-channel blocker, given before irradiation (9
Gy) at a dose of 62 nol kg
"1 orally did not produce any increase in survival compared to the vehicle-treated
group [113]. Based upon the efficacy of Verapamil in facilitating repair of photosensitization-radiation injury
and its prevention of the XD to XO conversion as reported by Athar et al. [58,59], this mechanistic feature of
Ca-channel blocker activity must be taken into account in examining their potential for radioprotectant activity.
It would also be useful to examine this mechanistic aspect of all radiorecovery agents.
Floersheim suggested that Ca-channel blockers might also act by blockade of cell death due to Ca
influx into cells following radiation injury [113]. However the antioxidative effects of Ca-eharmel blockers via
scavenging of free radicals was suggested as an alternative mechanism of action, which could involve stable
essential metalloelement chelate formation following hydrolysis of ester functional groups in vivo. Radical
scavenging reactivity of ammothiol radioprotectants and formation of their disulfides was also suggested as a
mechanism of their action in overcoming radical-mediated radiation injury [113]. A chelate mechanism for
radical scavenging by aminothiols is also plausible. Variations in activity of Ca-eharmel blockers were
suggested to be due to variations in bioavailability and receptor-bonding interaction [113].
Benzothiadiazepines and dihydropyridine Ca-channel blockers may also serve as chelating agents and
thus facilitate delivery of essential metalloelements to cells for de novo synthesis of essential metalloelement-
dependent repair enzymes. Calcium-Channel blockers have also been reported to decrease radiation-induced
esophagitis as a consequence of thoracic irradiation. Variation in blood flow was proposed to explain the
modified x-ray sensitivity of mouse tumor [113]. Calcium-Channel blocker-induced hypotension and tissue
anoxia was negated as the cause of radioprotectant activity of these agents, since other agents causing these
conditions had no radioprotecting activity [113]. Subsequently Floersheim reported [114] that 9 mol
Nifedipine kg
t given ip 3 hr before LDl00 irradiation (9.8 Gy, 0.9 Gy min") produced 83% survival. Again,
even though the radiation dose was a LD0oco dose, the 96% ethanol vehicle produced 61% survival while an
18% ethanol vehicle produced 28% survival.
A dose of 244 tmol Diltiazem hydrochloride kg
"t given sc to LD000 (10 Gy, 0.15 Gy min"1)
in’adiated male C3H mice produced 90,4 survival (P < 0.005) with treatment 30 min before irradiation or 75%
survival when given 10 min before irradiation. Treatment with 122 xmol kg under these conditions and 30
mm before irradiation produced 42% survival (P < 0.01) compared to 8% survival for vehicle (distilled water)-
treated mice. When given ip at 244 larnol kg 10 min before irradiation there was 100% survival (P < 0.005)
but only 80,4 survival (P < 0.005) when given 30 minutes before irradiation compared to 17% survival for
vehicle (distilled water)-treated mice. Treatment of female C3H mice given a 10.5 Gy dose of irradiation and a
dose of 244 lamol kg
"t Diltiazem ip 10 min before irradiation produced 54% survival (P < 0.005) compared
with 2% survival for vehicle (distilled water)-treated mice (70). When these mice were treated 30 min before
irradiation 59% survived (P < 0.005). Treatment 120 min before irradiation produced only 19% survival (P <
0.05).
Diltiazem given in distilled water to LD0o/0 (10 Gy, 15 cGy mm-) irradiated female BALB/c mice
before treatment with 244 lamol kg" ip or sc produced 100% survival (P < 0.005) compared to vehicle-treated
mice. The same 244 pmol kg
t dose given sc or ip to C57BL6, NMRI, orMAG mice produced significant (P <
0.01 strata-related differences in efficacy: 100%, 67%, or 8% surival respectively [114].
Nifedipine given 30 min before irradiation at doses of 2.3, 4.5, or 9 ktmol kg
t ip to LD00/30 (10.5 Gy,
0.15 Gy min") irradiated female C3H mice produced 0%, 40,4, or 79% (P _< 0.05) sau’vival, respectively,
compared to 6% survival for ethanol vehicle-treated control mice [114]. Nitrendipine given at doses of 139 or
278 tmol kg
l ip in distilled water to these mice 30 min before irradiation produced significant (P < 0.005)
increases of 25% or 29% survival respectively. When they were given 120 min before in’adiation they
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produced 22% or 30,6 survival (P 0.01) versus 0,6 survival for distilled water-treated control mice [114].
Vempamil, given to these mice at doses of 35 lamol kg"tip or Flunarizine, a piperazine Ca-channel blocker,
given to these mice at doses of 62 trnol kg
"t ip at 30 or 120 min tiller irradiation did not produce any increase
in survival compared to the 00/ survival for vehicle-treated mice 114].
Combinations of 61, 91, 122, or 244 Ixrnol kg Diltiazem and 7.5, 15, 30, 45, or 91 pmol kg"
Zn(II)(aspartate)2 given to female C3H mice before irradiation were studied in a factorial designed experiment.
Survivals for Diltiazem-treated mice were 33%, 44%, or 91% respectively while only the 91 lamol kg
"t dose of
Zn(II)(aspartate)2 was effective and produced 92% survival in these LD100/30 (10.5 Gy, 0.15 Gy min"l)
irradiated mice. However survival increased for nearly all combinations of Diltiazem and 45 lamol kg
t
Zn(II)(aspartate)2 to 50,6, 100%, or 92% [114].
Combinations of Diltiazem and Nifedipine were also studied using the factorial paradigm. A
synergistic increase in survival was found for increasing active doses of Nifedipine and Diltiazem from 61 to
122 prnol kg when given before irradiation [114]. No synergism was found for combinations of active doses
of Diltiazem, Nitrendipine, or Nifedipine and WR-2721. Synergism was observed for combinations of
Diltiazem ranging from 7.5, 15, 30, 61, or 122 lamol kg" and 17.5, 26, or 35 mmol DMSO kg", reaching 100%
survival for combinations of 122 larnol kg" Diltiazem and 17.5, 26, or 35 mmol DMSO kg in LD00/30
irradiated C3H mice treated before irradiation [114].
Koch [115] suggested that enhanced local blood flow caused by Ca-channel blockers might be
responsible for increased radiosensitivity due to the oxygen effect. The exchange by Koch [115] and
Floersheim [116] offered a number of spectflations concerning Ca-channel blockade in radiosensitization and
radioproteetion. These related to dose, chemical class, a possible role for small molecular mass solvent
molecules, as well as effects on metabolizing enzymes.
Interestingly, calcium was found to be elevated in heart, liver, lung, spleen, and kidney of adult male
albino rats but decreased in these tissues of female rats two months after 5 Oy ,t-irradiation [117]. While
cardiac Fe was elevated, Fe content decreased in all other tissues of male rats. There were no changes in heart
and lung Fe in female rats while liver, spleen, and kidney content decreased in female rats. Zinc was elevated
in the heart, decreased in lung and spleen, and unchanged in liver and kidney of both male and female rats
[117].
Radioprotectant Activity of Serotonin and Acyl Melatonin Homologs.
A review of Melatonin, N-acetyl-5-methoxytryptamine, antioxidant effects pointed out that Melatonin
is relatively non-toxic and protects against ionizing radiation injury [118]. This review cited the report of
Blickenstaff et al. [119] as having shown that Melatonin, the acetylated methoxyether of Serotonin, 5-
hydroxytryptarnine, produced 75 % survival in LD00/30 9.5 Gy whole-body irradiated male Swiss ND4 mice.
This was an increase in radiation protection compared to Serotonin, which produced only 20 % survival in the
same study. Intraperitoneal treatment of these mice with soybean oil solutions or suspensions of 1.1 mmol kg
1
acetyl (Melatonin), propionyl, butanoyl, pentanoyl, hexanoyl, oetanoyl, decanoyl, or hexadecanoyl analogs of
5-methyltryptamine 30 rain before irradiation produced survivals of 0 %, 43 % (P 0.0045), 32 %, 75 %, 95
%, 65 %, or 48 % respectively. In this experimental paradigm a 0.78 mmol WR-2721 kg
1 treatment produced
50 % survival. Radioprotectant activities of all Melatonin analogs were significantly different from vehicle-
treated mice and the activity of Melatonin was about equal to that of WR-2721. The increase in
radioprotectant activity was greatest for the hexanoyl and octanoyl derivatives, showing an increase in activity
with increasing lipophilicity. However, further increasing lipophilieity with the formation of still longer chain
amides lead to a decrease in activity, as is usually the case when lipophilicity is increased beyond some optimal
value. The observed radioprotectant potency as well as a lack of Melatonin toxicity was suggested to support
further study of Melatonin and these acyl homologs in circumstances ofhuman radiation injury [118].
These compounds can participate in coordinate-covalent bond formation with essential
metalloelements. The considerable enolic character of the amide carbonyl group and the proximity of the
weakly acidic indole amine offer possible coordination sites.
Vijayalaxmi et al. found that treatment hr before LD5030 8.15 Gy whole-body irradiation with ip
doses of 0.55 or 1.1 mmol Melatonin kg" suspended in soybean oil produced survivals of 50 % or 85 % (P
0.0080) respectively in CD2 mice versus 50% survival for vehicle-treated mice [120].
Karbownic et al. [121] recently reported that 440 tmaol Melatonin kg" given as a soybean oil
suspension ip to male Sprague-Dawley rats four times at 120, 90, 60, and 30 rain before whole-body 8 Gy
irradiation completely prevented the formation of 8-hydroxy-2’-deoxyguanosme and mierosomal membrane
rigidity in hepatocytes. Both of these damages are consequences of ionizing irradiation due to DNA or protein
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and lipid damage. It is noteworthy that these repairs of radiation injury were observed as soon as 12 hr after
treatment and irradiation.
Radioprotectant Activity of Substituted Anilines.
Using the same experimental paradigm that allowed the observation of radioprotectant activi.ty for
Melatonin homologs, Blickenstaff et al. [122] found that a series of substituted anilines had radioprotectant
activity. Intraperitoneal treatment of male Swiss ND4 mice with soybean oil solutions or suspensions of 780
xmol kg
1 4-arninobenzophenone, 4-arninopropiophenone, or the ethyl ketal of 4-arninopropiophenone
derivatives of aniline 30 min before LD00/30 9.5 Gy irradiation produced survivals of 100%, 100 % or 95 %
respectively versus 4 % survival for vehicle-treated mice. This radioprotectant paradigm also revealed a range
of 88 % to 55 % survivals for 780 pmol kg
1 treatments using: 4-Br; 4-CN; 3-Br; 4-NO2; 4-COCH3; 4-C1, 2-
CF3; 4-C1, 3-NO2; 4-CO2CH3; 3-C1; 4- CI; 4-CF3; 4-SCH3; 4-I; and 4-C1, 3-CF3 substituted anilines, survivals
ranged from 40 % down to 5 % for 3,4-diCl; H (aniline); 4-NH2; 4-CH3; 4-CONH2; 4-C1, 2-NO2; 4-C1,2-
CO2H; 4-COCtH4NH2; 4-CH2CH2OH; 4-CONHNH2; 4-OH; 4-C1,2-OCH3,5-CH3; and 4-F substituted anilines,
and 0% survival for 2-C1; 2-Br; 3,4,5-triC1; and 2-COC6H5,4-C1 substituted anilines [122].
In addition, Blickenstaff et al. [122] reported 95 % survival for 780 larnol kg
-1 2-NH2,5-Cl-pyriding
and 2-C1,5-NH2-pyridine treated mice, 79 % survival for 2-NH2,5-Br-pyridine treated mice; 5 % survival for 2-
NI-I2,4-CH3,6-OH-pyrimidine treated mice, 67 % survival for 5-Cl-l,2,3-benzotriazole treated mice, 20 %
survival for 2,6-diNH2-9,10-anthraqttinone treated mice, 14% survival for 1-NH2,4-Cl-napthalene treated mice,
and quite interestingly, 0 % survival for 4-Cl-acetylaniline treated mice even though the non-acetylated
compound produced 68% survival.
These substituted anilines represent an interesting class of radioprotectants. Their potential for
influencing essential metalloelement metabolism in facilitating repair of radiation injury remains to be
explained. Amino group sulfation or glucuronide formation offer potential pathways for the formation of
ligands capable of acting as chelating agents in facilitating tissue distribution of essential metalloelements
needed for de novo syntheses of essential metalloelement dependent enzymes required for repair of radiation
injury.
Radioprotectant Activity of Curcumin.
Curcumin, a I-diketone {1,7-bis(4’-hydroxy-3’-methoxyphenyl)-l,6-heptadiene-3,5-dione}, is a
yellow major component of Turmeric, a spice prepared from dried rhizomes of Curcuma longa L. Tumeric is
widely used to season foods in Asian countries and in particular, Indian Ctna3,. It is of particular interest to
note that Curcuma longa L is a fungus and fungi are well known for their high copper content. Since 13-
diketones are well known chelating agents [123,124] and this fully conjugated [5-diketone is likely to form
particularly stable Cu chelates as a result of the extended conjugation m this ligand, it may be that this ligand
exists as a Cu(II) chelate in fungi.
In 1993 Abraham, Sarma and Kesavan reported that Curcumin decreased chromosomal damage in ,-
irradiated mice [125]. A single oral administration of 27.2 nol Curcumin kg-
to male Swiss albino mice 2 hr
after whole-body 1.15 Gy irradiation significantly (P 0.01) reduced frequencies of micronucleated
polyehromatie erythrocytes (MPCEs) in bone marrow samples taken 24 hr after irradiation. Oral
administration of 13.6, 27.2, or 54.4 xmol Curcumin kg
t 2 hr before irradiation produced a dose related
decrease in MPCEs in bone marrow samples taken 24 hr after irradiation. Oral treatment with 27.2 tmol
Curcumin kg
1 2 hr before irradiation produced significant (P 0.05 to 0.01) time-dependent decreases in
MPCEs in bone marrow samples taken 24, 30, and 48 hr after irradiation. These results suggest that Curcumin
is useful in facilitating recovery from radiation injury..
Subsequently, lnano et al. [126] reported that feeding Curcumin decreased the incidence of marnmm3’
tumor m rats. A 1% Curcumin diet fed to 2.6 Gy whole-body irradiated pregnant Wistar-MS rats just prior to
pup birth (a mammary tumor imtiating procedure) and then implanted with diethylstilbestrol sustained release
pellets for 12 mo following weaning (a mammary tumor promoter regimen) caused a dramatically decreased
incidence of mammary tumor. Tumor formation decreased from 84.6 % for the control diet led group versus a
28 % incidence for the Curcumin fed rats. Feeding the diet containing Curcumin significantly (P<0.001)
reduced the number of rats with tumors and the number of tumors per rat and increased the latency period for
mammary tumor formation (P< 01001). Using this same pregnant Wistar-MS rat model of marnmm"
tumorogenesis and feeding a 1% Curcumin diet for a brief period from day-11 of pregnancy to day-23, the day
of birth, with 1.5 Gy whole-body irradiation on day-20, prior to birth of the rat pups, again significantly
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(P<0.0001) decreased the number of dams with mammary tumors from 19 (70.3 % incidence) for the control
group to 5 (18.5 % incidence) for the Cureumin fed rats. This Curcumin diet protocol also significantly
(P<0.0001) delayed development of mammary tumors in Curcumin fed rats. Eventually mammary tumors did
develop during the last two months of this 12-mo study [127]. Curcumin was fed for only 10 days in this study
while it was fed for yr in the first study (82). Thus further documenting and extending the application of
dietary Curcumin in preventing irradiation-induced mammary tumors.
CONCLUSIONS
Understanding essential metalloelement metabolism and its role in responding to radiation injur." as
mediated by immunomodulating cytokines does offer a renewed and potentially more effective approach to
recovery from all radiation syndromes. Copper, Fe, Mn, and Zn chelates have radioprotectant activity based
upon results obtained with treatment before radiation injury and some have been observed to have
radiorecovery activity based upon results obtained with treatment M’ter radiation injury. These compounds do
not prevent radiation injury however they do facilitate repair and recovery from radiation injury. They are also
far less toxic than existing radioprotectants. Existing radioprotectants have not been to shown to have
radioreeovery activity. New chelates with increased efficacy and still less toxicity may be found using
imaginative synthetic approaches to new ligands based upon existing compounds such as amino acids,
salicylates, as well as radioprotectant aminothiols Ca-channel blockers, acyl Melatonin analogs, substituted
anilines, and Cureumin. These chelates will also have potential for improving therapies of inflammatory
diseases, ulcers, seizures, neoplastic diseases, diabetes, and pathology associated with ischemia-reperfusion
Combination treatment with essential metalloelement chelates and aminothiols, Ca-channel blockers,
acyl Melatonin homologs, substituted anilines, and I-diketones such as Curcumin also offer an approach to
improving radiation recovery and treatment of other recognized disease states. Combinations of some of these
agents with essenti’al metalloelement chelates may lead to the development of new physiological, biochemical,
and pharmacological approaches to overcoming many disease states.
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